| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IAP; OA3; MER6 |
| Entrez GeneID | 961 |
| clone | 2H2B5 |
| WB Predicted band size | 35.2kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD47 (AA: 19-141) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CD47抗体的代表性文献及其摘要概括：
---
1. **文献名称**：*CD47 is a ligand for SIRPα on phagocytes and modulates phagocytosis*
**作者**：Oldenborg, P. A. et al.
**摘要**：首次揭示CD47通过与巨噬细胞表面SIRPα结合传递“别吃我”信号，抑制巨噬细胞对健康细胞的吞噬作用，为后续靶向CD47-SIRPα轴的癌症免疫治疗奠定理论基础。
---
2. **文献名称**：*The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors*
**作者**：Weiskopf, K. et al.
**摘要**：通过临床前研究证明抗CD47抗体可阻断肿瘤细胞表面CD47与巨噬细胞SIRPα的结合，增强巨噬细胞对多种实体瘤(如卵巢癌、膀胱癌)的吞噬作用，并联合放疗显著抑制肿瘤生长。
---
3. **文献名称**：*Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma*
**作者**：Chao, M. P. et al.
**摘要**：研究发现抗CD47抗体(如Hu5F9-G4)联合利妥昔单抗(抗CD20)可协同增强巨噬细胞对非霍奇金淋巴瘤细胞的吞噬作用，并在小鼠模型中实现肿瘤完全清除，推动该疗法进入临床试验。
---
4. **文献名称**：*CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma*
**作者**：Advani, R. et al.
**摘要**：首次I期临床试验表明，抗CD47抗体Hu5F9-G4联合利妥昔单抗在复发/难治性淋巴瘤患者中耐受性良好，客观缓解率达50%，证实靶向CD47的临床转化潜力。
---
**备注**：以上文献均为领域内里程碑研究，涵盖机制探索、临床前及临床转化。如需具体期刊信息或补充其他方向文献，可进一步说明。
CD47. a transmembrane glycoprotein widely expressed on normal cells, functions as a "don't eat me" signal by binding to signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells. This interaction inhibits phagocytosis, enabling healthy cells to evade immune surveillance. However, many cancers exploit this pathway by overexpressing CD47 to avoid macrophage-mediated clearance, making it a promising therapeutic target.
CD47-blocking antibodies aim to disrupt the CD47-SIRPα axis, thereby enhancing phagocytosis of cancer cells. Early studies demonstrated their potential in hematologic malignancies and solid tumors, often in combination with tumor-opsonizing antibodies (e.g., rituximab) to synergistically enhance macrophage activity. Challenges include on-target toxicity, as CD47 is expressed on erythrocytes and platelets, leading to anemia and thrombocytopenia in clinical trials. Next-generation agents, such as magrolimab (anti-CD47) with engineered Fc domains or SIRPα-Fc fusion proteins, aim to improve safety profiles by minimizing erythrocyte binding.
Research also explores CD47's role in immune checkpoint regulation, tumor stemness, and therapeutic resistance. Combination strategies with chemotherapy, radiation, or immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) are under investigation to overcome resistance mechanisms. Despite setbacks in some trials, CD47 remains a key focus in immuno-oncology, with ongoing efforts to refine targeting approaches and identify predictive biomarkers for patient stratification.
×
